Webinar Recording: Hot Melt Extrusion (HME) with Shin-Etsu, Leistritz and the St. Johns University

Hot Melt Extrusion is a well established technology used in ASDs. Besides the advantage of being a solvent free method some attributes of the API and polymer have to be considered like glass transition temperature and decomposition temperature.

Shin-Etsu, Leistritz, and Prof. Serajuddin from St. John‘s University gave very interesting presentations during a webinar on June 29th. You can see both presentations in the webinar recording. The webinar recording includes also the Questions and Answers session after the presentations.

The objectives of this webinar:

• How the extruder configuration can impact the ASD
• The advantages of HPMCAS in ASD
• How to optimize the extrusion process of HPMCAS

Watch Recording for free

First presentation: Hot melt extrusion for amorphous solid dispersion – Process Design and Applications

Speaker:
Kathrin Reusch, Leistritz GmbH

Presentation abstract:

The presentation will give a short background on solid dispersion by Hot Melt Extrusion showing specific process layouts of marketed extruded products.

Based on the case study: “Hot Melt Extrusion of Ritonavir/Lopinavir” process relevant parameters and their impact on the final product quality including scalability will be discussed.

Second Presentation: Development of HPMCAS-based amorphous solid dispersions by melt extrusion

Speaker:
Abu Serajuddin, PhD, Professor of Industrial Pharmacy, College of Pharmacy and Health Sciences, St. John’s University, Queens, New York, USA

Presentation abstract: 

Despite the recent interest in the use of solvent-free hot-melt extrusion (HME) method for the development of HPMCAS-based ASDs, its application in the development of marketed products has rather been limited. Indeed, out of 7 ASDs containing HPMCAS that have been marketed in recent years, only one was manufactured by HME. HME is not generally used as it requires very high temperature to extrude HPMCAS (≥170°C), where the polymer and drug may degrade. The situation may change based on recent studies in our laboratory. We studied the effects of three solid surfactants (poloxamer 188, poloxamer 407 and TPGS) and a model drug (itraconazole) in reducing complex viscosity and thus processing temperature of HPMCAS-based ASDs.

Watch Recording for free

Next webinars

In the next webinars of this series we will discuss the latest developments in the fields of amorphous solid dispersion (ASD) focusing on Excipient Key Attributes linked to the most popular technologies: Spray Drying and their Downstream Processing.

During these presentations Shin-Etsu, Leistritz, ProCepT, Alexanderwerk as well as invited speakers will give you more insights into ASD.

SECOND WEBINAR – Wednesday 22 September, 3pm CEST, 9am EST

Shin-Etsu, ProCepT, and Xedev will present recent advances in spray drying.

The objective of this web-seminar is to address:

• Spray drying ASDs with HPMCAS
• How spray drying parameters influence powder morphology
• Optimization of process parameters

THIRD WEBINAR – Thursday 28 October, 3pm CEST, 9am EST

Shin-Etsu and Alexanderwerk will give you more insights into down stream processing of spray dried dispersion.

The objective of this web-seminar is to address:

• Roller compaction as downstream process in spray drying
• Case study on roller compaction and tablet compression of a spray dried ASD with HPMCAS
• Alternative binder/disintegrant system with L-HPC (Low-substituted hydroxypropyl cellulose)

You will find the possibility to register for the second and third webinar on our webinar overview page.